Stage 1: History & Presentation (Timestamp: 6 Months Prior to Admission)
A 37-year-old female residing in an Indian metro (Delhi NCR) presents to the emergency department with a 1-week history of episodic left-sided facial, arm, and leg numbness, crampy pain, and motor weakness occurring 10 to 30 times daily.
HPI & Longitudinal Timeline:
- Over the preceding 3–6 months, she experienced several transient, un-evaluated episodes of facial numbness, transient subacute confusion ("speaking without making sense"), sudden flashes of light in her right peripheral vision, sensorineural hearing loss ("buzzing noise in left ear when conversing"), and focal myoclonic jerking of the left hand and forearm.
- Symptoms were episodic (lasting 5–10 minutes each) with incomplete resolution between attacks. She denies headaches or fever.
- PMH & Meds: Young-onset Type 2 Diabetes Mellitus (HbA1c 8.3%), Hypertension, Hyperlipidemia. Meds: Metformin 1000mg BD, Glimepiride 2mg, Atorvastatin 20mg.
- Social History: No travel outside India, no animal/insect exposures, non-smoker, no alcohol or illicit drug use. No family history of seizures.
Hello, Chief Resident here.
Key Findings:
A 37-year-old female with uncontrolled young-onset T2DM (HbA1c 8.3%) presents with frequent (10–30/day), brief, left-sided focal motor-sensory attacks, preceded by a 6-month history of multifocal stroke-like episodes (confusion, visual flashes, sensorineural hearing loss, myoclonus).
Differential Diagnoses:
1. MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) – 35%: Unifies young-onset diabetes, sensorineural hearing loss, and recurrent transient cortical/epileptic events.
2. Structural CNS Lesion (Tuberculoma / Neurocysticercosis) – 30%: Endemic region; accounts for subacute progression, focal seizures, and paroxysmal spells.
3. Autoimmune Encephalitis / CNS Vasculitis – 20%: Explains fluctuating, multifocal CNS deficits and episodic motor spasms.
4. Non-Ketotic Hyperglycemic Seizures / Movement Disorder – 15%: Driven by unmanaged diabetes presenting as focal seizures/dyskinesias.
Recommended Prioritized Tests:
1. Brain MRI with Contrast & MR Spectroscopy (assess cortical stroke-like lesions, lactate peak, or structural lesions).
2. Continuous Video-EEG (evaluate for focal subclinical seizures or ictal discharges during spells).
3. Serum and CSF Lactic Acid / Pyruvate (screen for mitochondrial dysfunction).
4. Lumbar Puncture (CSF microbiology, TB-PCR, autoimmune encephalopathy panel, oligoclonal bands).
5. Mitochondrial Genetic Testing (specifically targeting the m.3243A>G mutation).
Hello Attending Consultant here
Top 3 DDx:
1. MELAS (m.3243A>G) – young DM + SNHL + recurrent stroke-like/epileptic foci.
2. Neurocysticercosis/TB granuloma – endemic, multifocal irritative lesions.
3. NKH-related focal seizures – uncontrolled hyperglycemia driving epilepsia partialis continua-like spells.
Critique/Improvements (6 points):
- Prioritize STAT fingerstick glucose/ketones and EEG over genetics; NKH can mimic perfectly.
- Add DWI/ADC and ASL perfusion to MRI protocol—MELAS shows vasogenic edema + hyperperfusion, not arterial infarct.
- Serum lactate alone insufficient; obtain paired CSF:serum lactate ratio + MRS lactate peak.
- Defer broad autoimmune panel initially; yield low without encephalopathy or MRI limbic signal.
- Include CT chest/abdomen to exclude occult malignancy if paraneoplastic considered later.
- Genetic testing only after MRI/EEG/lactate; start with targeted m.3243A>G heteroplasmy in blood/urine, not full mito panel.
Hello, Expert Clinician here.
Best unifying diagnosis: MELAS/MIDD spectrum due to m.3243A>G mutation. The triad of young-onset diabetes, sensorineural hearing loss, and recurrent stroke-like episodes with focal seizures is classic and explains every element.
Top differentials:
- Moyamoya disease — fits young Asian woman with frequent stereotyped TIAs and vascular risk factors; fails to explain SNHL, myoclonus, or confusion.
- Focal epilepsy from structural lesion (NCC/TB) — endemic and plausible for ictal events; cannot unify diabetes and deafness.
- Non-ketotic hyperglycemic seizures — HbA1c 8.3% supports it; but visual flashes and hearing loss remain unexplained.
- Multiple sclerosis — brief paroxysmal symptoms can occur many times daily; less cohesive with metabolic phenotype.
Key pivot: Diabetes plus sensorineural hearing loss is the fingerprint of MIDD (m.3243A>G); add stroke-like episodes and the diagnosis narrows sharply to MELAS.
Most important next move: MRI brain with DWI and MR spectroscopy — cortical lesions crossing vascular territories with a lactate doublet on MRS would be near-confirmatory. Pair with EEG capturing a spell to confirm focal seizures, followed by m.3243A>G testing.
Teaching pearl: When "strokes" ignore vascular territories in a young patient with diabetes and deafness, think mitochondria, not atheroma.
Stage 2: Physical Examination & Initial Laboratory Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 36.7°C, HR 80 bpm, BP 114/71 mmHg, SpO2 100% room air. Well-appearing, alert, follows commands. Mild left nasolabial fold flattening. Neurologic: Involuntary, non-suppressible rhythmic myoclonic jerking and dystonic posturing of the left hand and forearm (focal motor seizures). Left upper/lower extremity motor weakness (4/5). Diminished sensation in left arm and leg. DTRs 2+ throughout.
Initial Laboratory Panel:
- Metabolic & Acid-Base: Persistently Elevated Plasma Lactic Acid (3.2 – 3.6 mmol/L) (lactic acidosis without systemic anion gap acidosis).
- Glycemic Profile: Blood Glucose 240 mg/dL, HbA1c 8.3%, Glucosuria & Ketonuria (40 mg/dL).
- Hemogram & Biochemistry: Leukocytosis (WBC 12.5 x 10³/µL, normalized to 8.4), Hb 14.0 g/dL, Platelets 273,000/µL. Normal BMP (Serum Creatinine 0.79 mg/dL), normal LFTs, normal Serum Ammonia (22 µmol/L), normal Vit B12 and Folate.
- Infectious & Autoimmune Screening: HIV 1/2, Syphilis (VDRL), TB Quantiferon, Hepatitis panel, Serum Cryptococcal Ag, Fungitell all negative.
Hello, Chief Resident here.
Updated Key Findings:
- Persistent elevated serum lactic acid (3.2–3.6 mmol/L).
- Left-sided epilepsia partialis continua with mild left hemiparesis and sensory deficit.
- Hyperglycemia with glucosuria and ketonuria.
- Negative preliminary infectious screen.
Probability-Based Diagnoses:
1. MELAS / MIDD Spectrum (m.3243A>G) – 70%: Persistent lactic acidosis, young-onset diabetes, sensorineural hearing loss, and focal stroke-like/ictal events form a classic, unifying mitochondrial phenotype.
2. Hyperglycemia-Induced Focal Seizures (EPC) – 15%: Supported by elevated glucose and ketonuria; explains epilepsia partialis continua but fails to unify persistent hyperlactatemia or prior hearing loss.
3. Structural Cortical Lesion (Granuloma/Atypical Infection) – 10%: Can cause focal motor seizures in an endemic setting; infection panel is negative so far.
4. Autoimmune Encephalitis / CNS Vasculitis – 5%: Accounts for focal, fluctuating deficits, though persistent metabolic/lactate abnormalities favor mitochondrial etiology.
Recommended Prioritized Tests:
1. Brain MRI with DWI, ASL, and MRS (assess for non-vascular territory cortical lesions, hyperperfusion, and lactate peak).
2. Targeted Genetic Testing for m.3243A>G (blood and urine heteroplasmy).
3. Continuous Video-EEG (characterize focal ictal discharges).
4. Lumbar Puncture (CSF lactate/pyruvate ratio, cell count, protein).
Hello Attending Consultant here
Top 3 DDx:
1. MELAS (m.3243A>G) – lactic acidemia + EPC + young DM + SNHL + non-vascular cortical events.
2. NKH/EPC from hyperglycemia – glucose 240 + ketonuria driving continuous focal motor seizures.
3. Focal cortical irritative lesion (NCC/TB) – endemic, residual possibility despite negative serologies.
Critique/Improvements (6 points):
- Obtain STAT EEG + fingerstick/ABG before MRI; confirm ictal vs. post-ictal and exclude evolving DKA.
- MRI must include DWI/ADC + ASL + MRS; MELAS = vasogenic edema, hyperperfusion, lactate doublet crossing territories.
- Paired CSF:serum lactate/pyruvate essential; serum alone non-specific.
- Start levetiracetam/benzodiazepine for EPC immediately; defer genetics until imaging/EEG.
- Urine mtDNA heteroplasmy higher yield than blood for m.3243A>G; order only post-MRI.
- Repeat lactate off metformin (confounder); add CK and resting lactate-pyruvate ratio.
Hello, Expert Clinician here.
Best unifying diagnosis: MELAS (m.3243A>G). Persistently elevated lactate in a young diabetic with sensorineural hearing loss, focal seizures, and left hemiparesis now essentially closes the diagnosis.
Top differentials:
- Non-ketotic hyperglycemic seizures/EPC — glucose 240 plus ketonuria can drive focal motor seizures; however, it cannot account for sustained hyperlactatemia at this glycemic level or the prior deafness.
- Structural irritative lesion (NCC/TB granuloma) — reasonable for EPC in India, but negative serologies and the systemic metabolic phenotype argue strongly against it.
- Inherited/acquired lactic acidosis — other mitochondrial or toxin-mediated causes lack the classic multisystem signature seen here.
Key pivot: Persistent, unexplained hyperlactatemia transforms vague stroke-like spells into a near-pathognomonic MELAS presentation.
Most important next move: MRI brain with DWI/ASL/MRS — demonstration of cortical lesions crossing vascular territories with a lactate doublet would be virtually confirmatory. Concurrently, treat the EPC with levetiracetam, hold metformin, and obtain urine/blood m.3243A>G testing.
Teaching pearl: In MELAS, lactate is the metabolic signature; when "TIAs" come with diabetes, deafness, and rising lactate, think mitochondria — and remember metformin can worsen the acidosis.
Stage 3: Neuroimaging, EEG & Lumbar Puncture (Timestamp: Hospital Days 2-4)
Neuroimaging & Diagnostic Studies:
- Non-contrast CT & CTA Head: Non-contrast CT showed an ill-defined hypodensity in the right frontotemporal region without mass effect or hemorrhage. CTA head/neck showed no large vessel occlusion or perfusion deficits (ruling out thromboembolic stroke).
- MRI Brain (Gold Standard Imaging): Demonstrates extensive T2/FLAIR hyperintensity with cortical diffusion restriction across the right temporal, parietal, and occipital lobes crossing classical vascular arterial boundaries, without mass effect or parenchymal enhancement.
- Continuous EEG: Interhemispheric asymmetry with loss of fast background frequencies over the right hemisphere; no overt status epilepticus.
- Lumbar Puncture (CSF Analysis): Clear; WBC 3 cells/µL, RBC 4, CSF Glucose 112 mg/dL, CSF Protein 39 mg/dL. CSF PCR multiplex negative. Negative Aquaporin-4 (AQP4-IgG) and negative MOG-IgG antibodies.
Hello, Chief Resident here.
Updated Key Findings:
Brain MRI reveals non-vascular territory cortical diffusion restriction and T2/FLAIR hyperintensity spanning the right temporal, parietal, and occipital lobes. CTA shows no LVO. CSF analysis is non-inflammatory with negative AQP4/MOG antibodies and PCR.
Probability-Based Diagnoses:
1. MELAS (m.3243A>G Mutation) – 90%: Classic MRI signature crossing arterial boundaries combined with young-onset DM, sensorineural hearing loss, focal seizures, and persistent hyperlactatemia.
2. Seronegative Autoimmune Encephalitis / Primary CNS Vasculitis – 5%: Multi-focal cortical involvement, though negative CSF markers and classic non-vascular distribution render this unlikely.
3. Post-Ictal / Hyperglycemic Encephalopathy – 3%: Can cause transient cortical restriction, but fails to explain multisystem phenotype or hyperlactatemia.
4. Atypical Vasculopathy / Moyamoya Variant – 2%: Effectively excluded by normal CTA.
Recommended Next Steps:
1. Targeted Genetic Testing for m.3243A>G point mutation (urine heteroplasmy preferred over blood).
2. Brain MR Spectroscopy (MRS) to confirm inverted lactate doublet peak at 1.33 ppm.
3. Initiate L-Arginine Protocol (IV/oral) for stroke-like episode mitigation along with CoQ10.
4. Discontinue Metformin (mitochondrial toxin risk) and avoid Valproate for seizure management.
Hello Attending Consultant here
Top 3 DDx:
1. MELAS (m.3243A>G) – non-vascular DWI+ cortical lesions + lactate + DM/SNHL/EPC.
2. Focal status/post-ictal edema (NKH-driven) – residual glycemic contribution to restriction.
3. Seronegative autoimmune/vasculitic encephalitis – low probability given acellular CSF/normal CTA.
Critique/Improvements (6 points):
- MRS is already implied in prior MRI; confirm lactate doublet retrospectively or re-acquire if missing—do not delay.
- Start IV L-arginine 0.5 g/kg immediately for acute stroke-like episode; do not await genetics.
- EEG shows interhemispheric slowing only—escalate ASM (LEV/LCM) and consider continuous EEG extension to capture subtle EPC.
- Urine > blood for m.3243A>G heteroplasmy; add muscle biopsy only if negative.
- Hold metformin permanently; switch to insulin, monitor serial lactate off-drug.
- Add serum CK, plasma amino acids, and resting L/P ratio; defer full mito NGS.
Hello, Expert Clinician here.
Best unifying diagnosis: MELAS (m.3243A>G). MRI showing cortical diffusion restriction crossing vascular territories in the right temporal–parietal–occipital lobes, combined with persistent lactatemia, focal seizures, young diabetes, and deafness, is virtually diagnostic.
Top differentials:
- Post-ictal / hyperglycemic cortical edema — can produce transient DWI changes and focal deficits, but cannot explain multi-lobar, non-vascular distribution or systemic lactate.
- Seronegative autoimmune encephalitis / CNS vasculitis — plausible with cortical FLAIR changes, yet acellular CSF, negative AQP4/MOG, and classic metabolic phenotype make it unlikely.
- Focal cortical dysplasia or low-grade glioma — chronic, but would not produce acute, multi-territorial diffusion restriction or lactic acidosis.
Key pivot: The MRI signature of diffusion-restricting lesions that ignore arterial boundaries is the decisive discriminator, separating metabolic stroke-like episodes from thromboembolic or inflammatory mimics.
Most important next move: Start IV L-arginine therapy immediately to blunt the acute stroke-like episode, stop metformin permanently, and obtain targeted urine/blood m.3243A>G testing with confirmatory MR spectroscopy for the lactate doublet.
Teaching pearl: MELAS lesions are cytotoxic-energy-failure strokes, not vascular occlusions — when DWI bright cortex crosses territories in a young diabetic with deafness and lactate, treat mitochondria first.
Stage 4: Targeted Genetic & Molecular Confirmation (Timestamp: Hospital Days 5-7)
Given the combination of stroke-like cortical lesions crossing vascular territories, focal myoclonic seizures, sensorineural hearing loss, young-onset diabetes, and persistent hyperlactatemia, specialized genetic testing was ordered:
- Targeted Mitochondrial DNA (mtDNA) Sequencing: Sanger sequencing and targeted NGS for common mitochondrial point mutations in peripheral blood leukocytes and urinary epithelial cells.
- Molecular Result: Identified the pathognomonic m.3243A>G point mutation in the MT-TL1 gene (encoding tRNA-Leucine [UUR]), confirming mitochondrial heteroplasmy.
Hello, Chief Resident here.
Updated Key Findings:
Targeted genetic testing definitively confirms the pathognomonic m.3243A>G point mutation in the MT-TL1 gene, establishing a conclusive molecular diagnosis of MELAS / MIDD spectrum.
Final Diagnostic Probabilities:
1. MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) / MIDD Spectrum – 100%: Confirmed by pathognomonic mtDNA genetics in a patient with young-onset diabetes, sensorineural hearing loss, hyperlactatemia, and stroke-like cortical lesions crossing vascular boundaries.
Recommended Next Steps in Management:
1. Acute & Maintenance Metabolic Therapy: Complete IV L-arginine protocol for the acute stroke-like episode; initiate long-term oral L-arginine and mitochondrial supplements (CoQ10, L-carnitine, Riboflavin).
2. Glycemic Management: Permanently discontinue metformin (mitochondrial toxin risk); transition to insulin therapy for tight glycemic control.
3. Seizure Control: Optimize non-mitochondrial toxic antiseizure medications (e.g., Levetiracetam, Lacosamide); strictly avoid Valproate due to hepatotoxicity and mitochondrial inhibition.
4. Cardiovascular & Multidisciplinary Workup: Obtain baseline ECG and Echocardiogram to screen for mitochondrial cardiomyopathy or conduction defects; perform formal audiology evaluation.
5. Genetic Counseling: Offer maternal lineage screening and heteroplasmy testing for family members.
Hello Attending Consultant here
Top 3 DDx:
1. MELAS (m.3243A>G confirmed) – pathognomonic genetics + phenotype.
2. MIDD spectrum overlap – same mutation, diabetes/deafness dominant.
3. Secondary mitochondrial decompensation (metformin/hyperglycemia) – residual contributor now excluded.
Critique/Improvements (6 points):
- Initiate IV L-arginine 0.5 g/kg/day x 3–5 days immediately if not already started; transition to oral 0.15–0.3 g/kg/day lifelong.
- Add taurine and high-dose CoQ10/idebenone; evidence stronger than carnitine/riboflavin alone.
- Baseline ECG/echo + Holter mandatory—screen for WPW/cardiomyopathy before discharge.
- Formal audiometry + ophthalmology (pigmentary retinopathy) now; annual thereafter.
- Maternal cascade testing + genetic counseling; quantify heteroplasmy in urine/blood for prognosis.
- Strict valproate/metformin avoidance list in discharge summary; insulin + non-hepatotoxic ASM only.
- Serial lactate + MRS follow-up at 3 months to gauge recovery.
Hello, Expert Clinician here.
Best unifying diagnosis: MELAS / MIDD spectrum, molecularly confirmed by the m.3243A>G mutation in MT-TL1. The genetics now seal the phenotype of young diabetes, sensorineural deafness, focal seizures, and stroke-like lesions crossing vascular territories.
Top differentials: Effectively resolved; MIDD alone lacks stroke-like episodes, while structural, autoimmune, and hyperglycemic mimics were excluded by MRI pattern, acellular CSF, and persistent lactatemia.
Key pivot: Detection of the m.3243A>G point mutation transforms a strong clinical suspicion into definitive mitochondrial disease and directly dictates therapy.
Most important next move: Complete IV L-arginine and transition to lifelong oral L-arginine plus CoQ10; permanently stop metformin, switch to insulin, and strictly avoid valproate. Add baseline ECG, echocardiogram, audiology, and maternal genetic counseling.
Teaching pearl: In mitochondrial disease, genotype drives management — one base change (m.3243A>G) mandates arginine therapy, reshapes diabetes and seizure treatment, and triggers family screening.
Stage 5: Final Unifying Diagnosis & Clinical Management (Timestamp: Follow-up & Discharge)
Final Unifying Diagnosis: MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes) presenting with cortical stroke-like lesions crossing vascular boundaries, focal motor seizures, sensorineural hearing loss, diabetes mellitus, and persistent hyperlactatemia.
Treatment Plan:
- Acute Management: Intravenous L-Arginine bolus and continuous infusion (to increase microvascular nitric oxide synthesis and reduce stroke-like ischemia).
- Antiepileptic Therapy: Levetiracetam (1000mg BD) (strictly avoiding Valproic Acid due to mitochondrial POLG toxicity).
- Metabolic Management: Discontinuation of Metformin (to prevent worsening lactic acidosis), initiation of Coenzyme Q10 / L-Carnitine supplementation, insulin for glycemic control, and provision of an emergency metabolic protocol letter.
Outcome: Resolution of focal motor seizures, regression of stroke-like MRI hyperintensities, stabilization of serum lactate, and referral for maternal line genetic counseling.
Hello, Chief Resident here.
Key Findings:
Molecularly confirmed MELAS (m.3243A>G mutation) presenting with non-vascular stroke-like cortical lesions, focal motor seizures, persistent lactic acidosis, young-onset diabetes, and sensorineural hearing loss, with clinical and radiological recovery following IV L-arginine and metabolic optimization.
Differential Diagnoses:
1. MELAS Syndrome (m.3243A>G) – 95%: Confirmed by pathognomonic mtDNA genetics and classic clinical-radiological phenotype.
2. MIDD Phenotype Overlap – 4%: Shares the m.3243A>G mutation, diabetes, and deafness, though stroke-like episodes fulfill MELAS criteria.
3. Other Primary Mitochondrial Encephalopathies – 1%: Excluded by targeted MT-TL1 sequencing.
Next Steps & Management Plan:
1. Long-Term Metabolic Therapy: Transition to lifelong oral L-arginine, high-dose CoQ10, L-carnitine, and taurine.
2. Seizure & Glycemic Control: Continue Levetiracetam and insulin; strictly avoid Metformin, Valproate, and other mitochondrial toxins.
3. Multisystem Surveillance: Baseline ECG, Holter monitoring, and echocardiography to screen for mitochondrial cardiomyopathy or conduction defects; annual audiometry and ophthalmology.
4. Follow-Up: Repeat brain MRI with MRS and serum/urine lactate in 3–6 months.
5. Genetic Counseling: Maternal lineage screening and heteroplasmy quantification for family members.
Hello Attending Consultant here
Top 3 DDx:
1. MELAS (m.3243A>G confirmed) – definitive.
2. MIDD overlap – same mutation, milder CNS phenotype.
3. Secondary decompensation (resolved metformin/hyperglycemia contribution).
Critique/Improvements (6 points):
- Confirm full IV L-arginine dosing (0.5 g/kg bolus then infusion) completed; transition promptly to oral 0.15–0.3 g/kg/day lifelong.
- Add taurine 100 mg/kg/day and idebenone; superior evidence vs carnitine alone for stroke-like prophylaxis.
- Mandate pre-discharge ECG + echo + Holter; screen WPW/cardiomyopathy (high sudden-death risk).
- Formal audiometry + retinal exam now; schedule annual multisystem surveillance (cardiac, endocrine, neuro).
- Quantify heteroplasmy (urine/blood/muscle) for prognosis; expedite maternal cascade testing + counseling.
- Issue written emergency letter listing toxin avoidance (valproate, metformin, linezolid, propofol); insulin + LEV only.
- Plan 3-month MRI/MRS + lactate to document lesion regression and guide arginine titration.
Hello, Expert Clinician here.
Best unifying diagnosis: MELAS syndrome, definitively confirmed by the m.3243A>G mutation, explaining non-vascular stroke-like lesions, focal seizures, diabetes, deafness, and lactic acidosis.
Top differentials: Resolved — MIDD alone cannot account for stroke-like episodes; metabolic, structural, and autoimmune mimics were excluded by imaging, CSF, and genetics.
Key pivot: The m.3243A>G mutation converted a syndromic suspicion into a treatable molecular diagnosis, driving arginine therapy and permanent avoidance of mitochondrial toxins.
Most important next move: Transition to lifelong oral L-arginine, CoQ10, and taurine; maintain insulin and levetiracetam while strictly avoiding metformin, valproate, propofol, and linezolid. Complete baseline ECG, echocardiogram, Holter, audiology, and retinal screening, followed by maternal cascade genetic counseling and 3-month MRI/MRS with serial lactate.
Teaching pearl: In MELAS, management is as critical as diagnosis — arginine rescues acute strokes, but long-term survival hinges on toxin avoidance, cardiomyopathy surveillance, and family heteroplasmy screening.